Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS) (HOMEOSTASIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00547729
Recruitment Status : Completed
First Posted : October 23, 2007
Last Update Posted : June 13, 2016
Information provided by (Responsible Party):
St. Jude Medical

Brief Summary:
Most people with heart failure take a number of medications that work in different ways. Patients and their families need to keep track of prescribed medications and follow instructions on how much to take and when to take them. Currently, doctors are guided primarily by symptoms. The device being studied in this trial (called the HeartPOD™ System) monitors heart function from inside your body and alerts the patient and physician of necessary changes to your medication.

Condition or disease Intervention/treatment Phase
Heart Failure Device: HeartPOD™ System Phase 1 Phase 2

Detailed Description:
The Sponsor believes that direct measurements from your heart may provide an accurate, reliable and medically acceptable way of telling you and your doctor that your CHF is worsening hours to days before the above symptoms would develop and you would notice. This may enable you and your doctor to take preventative measures and avoid hospitalization.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients: A Prospective, Multi-center, Non-randomized, Open Label Study.
Study Start Date : March 2005
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: HeartPOD™ System
Implantation of HeartPOD™ System
Device: HeartPOD™ System
HeartPOD™ device automatically measures left heart pressures throughout the day.

Primary Outcome Measures :
  1. Freedom from Major Adverse Cardiac and Neurological Events (MACNE) at 6 weeks. [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 and < 85.
  • Documented history of congestive heart failure resulting from ischemic or non-ischemic cardiomyopathy with systolic or diastolic dysfunction of at least 6 months duration.
  • Patients with LVEF < 40% should receive maximally tolerated doses of ACE-I (or ARB if ACE-I is not tolerated), beta blockers, and anti-aldosterone therapy. The combination of hydralazine and nitrates should be considered in the persistently symptomatic African American patient.
  • A history of NYHA Class II (OUS only), III or IV symptoms.
  • Minimum of one (1) prior hospital admission within the last 12 months for exacerbation of CHF or one (1) presentation to the Emergency Department or Clinic requiring parenteral diuretic, vasodilator, inotrope, nesiritide, or equivalent treatment.
  • Female subjects of childbearing potential must have a negative pregnancy test within seven (7) days before the procedure.
  • Central venous vascular access.
  • Capable of Valsalva maneuver with airway pressure > 40 mm Hg for 10 seconds.
  • The subject and the treating physician agree that the subject will comply with all required post-procedure follow-up, and that the patient is capable of correct device use as outlined in the protocol.
  • Written informed consent.

Exclusion Criteria:

  • Intractable HF with resting symptoms despite maximal medical therapy or active listing for cardiac transplantation (< 6 months survival expected).
  • Resting systolic blood pressure < 90 or > 180 mmHg.
  • Acute MI, unstable ischemic syndrome within the last 6 weeks.
  • Percutaneous coronary intervention (PCI) or cardiac surgery performed or planned within 6 weeks.
  • Coexisting stenotic valve lesions, vegetations, hypertrophic cardiomyopathy, amyloidosis or other infiltrative heart disease, constrictive, restrictive disease, tamponade, or moderate or large pericardial effusion.
  • Subject has a history of deep venous thrombosis or pulmonary embolism.
  • Surgical correction of congenital heart disease involving atrial septum.
  • CVA or TIA within 6 months. History of uncorrected cerebral vascular disease.
  • Atrial or ventricular thrombus, tumor or systemic thromboembolism.
  • Chronic atrial fibrillation.
  • Symptomatic bradyarrhythmia or sustained VT/VF unless successfully treated with cardiac rhythm management device for 6 weeks.
  • Atrial septal defect or patent foramen ovale > 2 mm in diameter.
  • Life expectancy < 1 year from malignancy, primary pulmonary hypertension, renal, hepatic, or neurological condition, etc.
  • Gastrointestinal bleeding during the last 6 months.
  • Coagulopathy or uninterruptible anticoagulation therapy or unable to take antiplatelet medications.
  • Creatinine > 2.5 gm/dl
  • Temperature > 37.8C or white blood cell count (WBC) > 13,000/mm3.
  • The subject is currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00547729

United States, California
Scripps Green Hospital
La Jolla, California, United States, 92037
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43210
United States, Oklahoma
Oklahoma Heart Hospital
Oklahoma City, Oklahoma, United States, 73120
Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004
New Zealand
University of Auckland
Auckland, New Zealand
Christchurch Hospital
Christchurch, New Zealand
Sponsors and Collaborators
St. Jude Medical
Study Chair: William T. Abraham, MD, FACC Ohio State University
Principal Investigator: Henry Krum, MD Monash University/Alfred Hosptial

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: St. Jude Medical Identifier: NCT00547729     History of Changes
Other Study ID Numbers: HP-05-04/HP-12-04
First Posted: October 23, 2007    Key Record Dates
Last Update Posted: June 13, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by St. Jude Medical:
Heart Failure
Left Atrial Pressure Monitoring

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases